{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:59:28Z","timestamp":1770980368116,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,7]],"date-time":"2008-01-07T00:00:00Z","timestamp":1199664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1186\/1471-244x-8-3","type":"journal-article","created":{"date-parts":[[2008,1,8]],"date-time":"2008-01-08T07:23:55Z","timestamp":1199777035000},"source":"Crossref","is-referenced-by-count":27,"title":["Evaluating dose response from flexible dose clinical trials"],"prefix":"10.1186","volume":"8","author":[{"given":"Ilya","family":"Lipkovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Mallinckrodt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doug","family":"Faries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P","family":"Houston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,7]]},"reference":[{"key":"447_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0006-3223(02)01867-X","volume":"53","author":"CH Mallinckrodt","year":"2003","unstructured":"Mallinckrodt CH, Sanger TM, Dube S, DeBrota DJ, Molenberghs G, Carroll RJ, Potter WZ, Tollefson GD: Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003, 53: 754-60. 10.1016\/S0006-3223(02)01867-X.","journal-title":"Biol Psychiatry"},{"key":"447_CR2","first-page":"95","volume-title":"Statistical Models in Epidemiology: The Environment and Clinical Trials","author":"JM Robins","year":"1999","unstructured":"Robins JM: Marginal Structural Models versus Structural Nested Models as Tools for Causal Inference. Statistical Models in Epidemiology: The Environment and Clinical Trials. Edited by: Halloran ME, Berry D. 1999, New York: Springer-Verlag, 95-134."},{"key":"447_CR3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n M, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology. 2000, 11: 550-560. 10.1097\/00001648-200009000-00011.","journal-title":"Epidemiology"},{"key":"447_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","volume":"11","author":"M Hern\u00e1n","year":"2000","unstructured":"Hern\u00e1n M, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000, 11: 561-570. 10.1097\/00001648-200009000-00012.","journal-title":"Epidemiology"},{"key":"447_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1198\/016214501753168154","volume":"96","author":"M Hern\u00e1n","year":"2001","unstructured":"Hern\u00e1n M, Brumback B, Robins JM: Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001, 96: 440-448. 10.1198\/016214501753168154.","journal-title":"J Am Stat Assoc"},{"key":"447_CR6","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/sim.1144","volume":"21","author":"MA Hern\u00e1n","year":"2002","unstructured":"Hern\u00e1n MA, Brumback B, Robins JM: Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med. 2002, 21: 1689-1709. 10.1002\/sim.1144.","journal-title":"Stat Med"},{"key":"447_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/(SICI)1097-0258(19970115)16:1<81::AID-SIM473>3.0.CO;2-0","volume":"16","author":"A Rotnitzky","year":"1997","unstructured":"Rotnitzky A, Robins JM: Analysis of semiparametric regression models with non-ignorable non-response. Stat Med. 1997, 16: 81-102. 10.1002\/(SICI)1097-0258(19970115)16:1<81::AID-SIM473>3.0.CO;2-0.","journal-title":"Stat Med"},{"key":"447_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"P Rosenbaum","year":"1983","unstructured":"Rosenbaum P, Rubin D: The central role of propensity score in observational studies for causal effects. Biometrika. 1983, 70: 41-55. 10.1093\/biomet\/70.1.41.","journal-title":"Biometrika"},{"key":"447_CR9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1001\/archpsyc.60.12.1218","volume":"60","author":"M Tohen","year":"2003","unstructured":"Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A: A 12-week double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003, 60: 1218-26. 10.1001\/archpsyc.60.12.1218.","journal-title":"Arch Gen Psychiatry"},{"key":"447_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","volume":"17","author":"PV Tran","year":"1997","unstructured":"Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997, 17: 407-18. 10.1097\/00004714-199710000-00010.","journal-title":"J Clin Psychopharmacol"},{"key":"447_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978, 133: 429-435.","journal-title":"Br J Psychiatry"},{"key":"447_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fisbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-76.","journal-title":"Schizophr Bull"},{"key":"447_CR13","first-page":"677","volume-title":"Proceedings of the American Statistical Association, Biopharmaceutical Section","author":"I Lipkovich","year":"2006","unstructured":"Lipkovich I, Mallinckrodt C, Faries D: Exploring dose response in flexible dose trials using marginal structural models. Proceedings of the American Statistical Association, Biopharmaceutical Section. 2006, Alexandria, VA. American Statistical Association, 677-682."},{"key":"447_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/oso\/9780198524847.001.0001","volume-title":"Analysis of Longitudinal Data","author":"PJ Diggle","year":"2002","unstructured":"Diggle PJ, Heagerty P, Liang K: Analysis of Longitudinal Data. 2002, Oxford: University Press, 265-280. second","edition":"second"},{"key":"447_CR15","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Tripartite Guideline E4. Dose-response information to support drug registration. [ http:\/\/www.ich.org ]"},{"key":"447_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","volume":"14","author":"CM Beasley","year":"1996","unstructured":"Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharm. 1996, 14: 111-123. 10.1016\/0893-133X(95)00069-P.","journal-title":"Neuropsychopharm"},{"key":"447_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0924-977X(96)00392-6","volume":"7","author":"CM Beasley","year":"1997","unstructured":"Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN: Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharm. 1997, 7: 125-137. 10.1016\/S0924-977X(96)00392-6.","journal-title":"Eur Neuropsychopharm"},{"key":"447_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","volume":"26","author":"BJ Kinon","year":"2006","unstructured":"Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG: A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006, 26: 157-162. 10.1097\/01.jcp.0000204137.82298.06.","journal-title":"J Clin Psychopharmacol"},{"key":"447_CR19","first-page":"S281","volume":"9","author":"BJ Kinon","year":"2006","unstructured":"Kinon BJ, Volavka J, Stauffer V, Edwards B, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson D, Citrome L: Standard and higher doses of olanzapine in acutely ill patients with schizophrenia with suboptimal prior response: a randomized double-blind fixed dose study [abstract]. Int J Neuropsychopharmacol. 2006, 9: S281-","journal-title":"Int J Neuropsychopharmacol"},{"key":"447_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/01.jcp.0000167791.70664.d4","volume":"25","author":"I Lipkovich","year":"2005","unstructured":"Lipkovich I, Baron D, Houston J, Ahl J, Rotelli M: Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments. J Clin Psychopharmacol. 2005, 25: 381-6. 10.1097\/01.jcp.0000167791.70664.d4.","journal-title":"J Clin Psychopharmacol"},{"key":"447_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/aje\/kwi208","volume":"162","author":"KM Mortimer","year":"2005","unstructured":"Mortimer KM, Neugebauer R, van der Laan M, Tager IB: An application of model-fitting procedures for marginal structural models. Am J Epidemiol. 2005, 162: 382-8. 10.1093\/aje\/kwi208.","journal-title":"Am J Epidemiol"},{"key":"447_CR22","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1097\/01.qai.0000248344.95135.8d","volume":"43 Suppl 1","author":"ML Petersen","year":"2006","unstructured":"Petersen ML, Wang Y, van der Laan MJ, Bangsberg DR: Assessing the effectiveness of antiretroviral adherence interventions. Using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr. 2006, 43 Suppl 1 (): S96-S103.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"447_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/1541-0420.00034","volume":"59","author":"BA Brumback","year":"2003","unstructured":"Brumback BA, Greenland S, Redman M, Kiviat N, Diehr P: The intensity-score approach to adjusting for confounding. Biometrics. 2003, 59: 274-285. 10.1111\/1541-0420.00034.","journal-title":"Biometrics"},{"key":"447_CR24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1198\/016214501753382327","volume":"96","author":"SA Murphy","year":"2001","unstructured":"Murphy SA, van der Laan MJ, Robins JM: Marginal mean models for dynamic regimes. J Am Stat Assoc. 2001, 96: 1410-1423. 10.1198\/016214501753382327.","journal-title":"J Am Stat Assoc"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-8-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-8-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-8-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-8-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T03:12:57Z","timestamp":1708485177000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-8-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-8-3","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,7]]},"article-number":"3"}}